Home/ Stocks/ APVO

Aptevo Therapeutics Inc

APVO XNAS

$1.24 -0.02 (-1.57%) ▼ 15-min delayed

Open

$1.30

High

$1.32

Low

$1.20

Volume

33.1K

Market Cap

$2.62M

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 33 Website →

Related Market News

No specific coverage for APVO yet. Check out our latest market news or earnings calendar.

Get APVO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Aptevo Therapeutics Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.